Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Century Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 70 | 65 | −5 |
| Shares | 29.6M | 22.6M | −6.95M (−23.5%) |
| Value | $14.1M | $12.6M | −$1.44M (−10.2%) |
New holders (21)
Institutions that held Century Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 812,213 | $453.8K | 0.00% |
| Gsa Capital Partners LLP | 466,606 | $261.0K | 0.02% |
| Jane Street Group, LLC | 444,590 | $248.4K | 0.00% |
| Marshall Wace, LLP | 139,707 | $78.2K | 0.00% |
| HRT Financial LP | 111,064 | $62.0K | 0.00% |
| Raymond James Financial Inc | 91,323 | $51.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 89,975 | $50.3K | 0.00% |
| Qube Research & Technologies Ltd | 67,737 | $37.8K | 0.00% |
| Lazard Asset Management LLC | 62,947 | $35.0K | 0.00% |
| Prudential Financial Inc | 45,400 | $25.4K | 0.00% |
| Jain Global LLC | 40,276 | $22.5K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 36,884 | $20.6K | 0.00% |
| Abel Hall, LLC | 17,582 | $9.82K | 0.00% |
| Quadrant Private Wealth Management, LLC | 15,286 | $8.54K | 0.00% |
| Two Sigma Securities, LLC | 11,767 | $6.57K | 0.00% |
| Ground Swell Capital, LLC | 10,176 | $5.68K | 0.01% |
| Advisors Asset Management, Inc. | 8,498 | $4.75K | 0.00% |
| Cubist Systematic Strategies, LLC | 1,978 | $1.10K | 0.00% |
| Point72 (DIFC) Ltd | 1,749 | $977 | 0.00% |
| Essential Partners LLC | 119 | $66 | 0.00% |
| IFP Advisors, Inc | 6 | $3 | 0.00% |
Sold out (26)
Institutions that held Century Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.